Gentamicin pharmacokinetics in patients with malignancies.
about
Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms.Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteriaPopulation pharmacokinetic analysis of vancomycin in patients with hematological malignanciesAminoglycoside dosing weight correction factors for patients of various body sizes.Population pharmacokinetics of gentamicin in patients with cancer.Nonparametric approach to population pharmacokinetics in oncology patients receiving aminoglycoside therapy.Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemiaAminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups.Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients.Pharmacokinetics of vancomycin in adult cancer patients.Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients.Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.Influence of diagnostic and treatment factors in the population pharmacokinetics of gentamicin.Population analysis of once-daily dosing of gentamicin in patients with neutropenia.Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.Correlation of aminoglycoside and vancomycin pharmacokinetic parameters.
P2860
Q33694513-DD60F8A3-8BC7-4F6F-A702-A9D8C1C7ADBBQ33976467-B678575A-BA0D-4A15-B181-40F62AB75E7FQ34228227-445B5275-DC57-49E0-B5ED-15990B93F593Q35111974-B166A0F2-B5D1-4EB8-B426-CEF565DF2589Q35802610-053AF562-B027-492F-9989-EB5CA3244DE4Q35814454-E7CCDCE5-2011-4445-88B5-7893BEE8036AQ35867409-CDE0EC48-BC12-432E-8100-D6F29BB79E17Q36725610-8D177718-0F56-40B8-A0EE-4E8FBBD5687FQ37695055-E39415E0-2551-4ADD-A445-CC6693B92AEBQ40643970-A46B0A05-DEE9-427D-BC98-634317066424Q42643110-D1BAE371-8EF1-4061-B99E-45A6AE911FD7Q44484329-031FCD1C-6D49-4BD1-AFFB-13222C00DFD1Q47574617-724B4DBF-E80A-4F8B-83FF-A2AE98CFD11BQ50156073-0D32251C-508E-4ADF-AE05-D0A3651B0761Q50875106-0EDC8B0C-C8BB-4D8B-AD0A-2BD10ACD244BQ51575000-A5F13AFF-52A3-4F1A-B9EA-CF0C7BEE66A3Q52388432-41168C7D-C910-4543-84D9-48B0627742FD
P2860
Gentamicin pharmacokinetics in patients with malignancies.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Gentamicin pharmacokinetics in patients with malignancies.
@en
type
label
Gentamicin pharmacokinetics in patients with malignancies.
@en
prefLabel
Gentamicin pharmacokinetics in patients with malignancies.
@en
P2093
P2860
P356
P1476
Gentamicin pharmacokinetics in patients with malignancies.
@en
P2093
Bertino JS Jr
P2860
P304
P356
10.1128/AAC.35.7.1501
P407
P577
1991-07-01T00:00:00Z